280
Participants
Start Date
March 2, 2022
Primary Completion Date
December 25, 2025
Study Completion Date
December 25, 2025
six courses of zanubrutinib, rituximab and lenalidomide
Patients in ZR2 group will receive 6 cycles of zanubrutinib 160mg bid, day 1-21, orally, lenalidomide 25mg qd, day 2-11, orally, rituximab 375mg/m², day 1, intravenously, every 21 days.
six courses of rituximab combined with low-dose CHOP
Patients in R-miniCHOP group will receive rituximab 375 mg/m² on day 1, cyclophosphamide 400 mg/m², doxorubicin 25 mg/m², and vincristine 1 mg on day 2, and prednisone 40 mg/m² on days 2-6, every 21 days.
RECRUITING
Ruijin Hospital, Shanghai
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Ningbo No. 1 Hospital
OTHER
National Naval Medical Center
FED
Shanghai Fengxian District Central Hospital
OTHER
YANCHENG NO.1 PEOPLE'S HOSPITAL
UNKNOWN
The First Affiliated Hospital of Nanchang University
OTHER
Affiliated Hospital of Nantong University
OTHER
Sir Run Run Shaw Hospital
OTHER
Northern Jiangsu People's Hospital
OTHER
The First People's Hospital of Changde City
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
Changzhou No.2 People's Hospital
OTHER
The Affiliated Hospital of Xuzhou Medical University
OTHER
Huai'an First People's Hospital
OTHER
Taizhou Hospital
OTHER
The First People's Hospital of Kunshan
OTHER
First Affiliated Hospital of Fujian Medical University
OTHER
Huadong Hospital
OTHER
Henan Provincial People's Hospital
OTHER
First Hospital of China Medical University
OTHER
Shandong Provincial Hospital
OTHER_GOV
HARBIN THE FIRST HOSPITAL
UNKNOWN
The First Hospital of Jilin University
OTHER
Hunan Cancer Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
THE FIRST AFFILIATED HOSPITAL
UNKNOWN
The Second Affiliated Hospital of Dalian Medical University
OTHER
SUZHOU HONGCI HEMATOLOGY HOSPITAL
UNKNOWN
Ruijin Hospital
OTHER